Summit Therapeutics $SMMT

Health Care · NASDAQ

$9.95
-0.62 (-5.87%)
As of Nov 20, 2026, 4:05 PM EST
Price history
Loading chart…
Today's analyst average Analyst average over timeIndividual analyst targets Analyst history starts Sep 30, 2026, the first target we tracked for SMMT.

Summit Therapeutics (SMMT) is trading down at $9.95 (-5.87%) on NASDAQ, as of the latest quote. It is a Russell 1000 constituent in the Health Care sector.

IPO: March 5, 2015 · $9.90 offering · NASDAQ

Analyst price targets on SMMT

Current price targets from 4 firms average $29.7, median $33.5, ranging from $11.9 to $40 — the average is 199% above the current $9.95. Each is tracked to its date and scored the same way a member's call is.

4 targets, newest first. Open a row for its source and scoring.

DateNov 15, 2026 FirmJefferies RatingBuy · reiterates Targetat $14.2 · $30 +112% Horizonby Nov 2027 StatusOpen

Entry price $14.2, the close nearest Nov 15, 2026, when the target was reported; the target is +112% from it.

Horizon No horizon stated, so it is tracked over the 12-month default, to Nov 2027.

Scoring Open: judged on the close on Nov 15, 2027.

Source Jefferies reiterates Summit Therapeutics stock rating after FDA setback Investing.com · Nov 15, 2026 · opens the publisher's site
Jefferies reiterated a Buy rating and $30.00 price target on Summit Therapeutics plc
DateNov 15, 2026 FirmStifel RatingBuy · lowers Targetat $14.2 · $37 +161% Horizonby Nov 2027 StatusOpen

Entry price $14.2, the close nearest Nov 15, 2026, when the target was reported; the target is +161% from it.

Horizon No horizon stated, so it is tracked over the 12-month default, to Nov 2027.

Scoring Open: judged on the close on Nov 15, 2027.

Source Jefferies reiterates Summit Therapeutics stock rating after FDA setback Investing.com · Nov 15, 2026 · opens the publisher's site
Stifel subsequently lowered its price target on Summit Therapeutics to $37 from $38 but maintained a Buy rating.
DateOct 5, 2026 FirmBernstein RatingMarket Perform · reiterates Targetat $17.3 · $11.9 -31% Horizonby Oct 2027 StatusOpen

Entry price $17.3, the close nearest Oct 5, 2026, when the target was reported; the target is -31% from it.

Horizon No horizon stated, so it is tracked over the 12-month default, to Oct 2027.

Scoring Open: judged on the close on Oct 5, 2027.

Source Bernstein reiterates Summit Therapeutics stock rating on trial concerns Investing.com · Oct 5, 2026 · opens the publisher's site
Bernstein reiterates Summit Therapeutics stock rating on trial concerns
DateSep 30, 2026 FirmCitizens JMP RatingMarket Outperform · reiterates Targetat $16.9 · $40 +137% Horizonby Sep 2027 StatusOpen

Entry price $16.9, the close nearest Sep 30, 2026, when the target was reported; the target is +137% from it.

Horizon No horizon stated, so it is tracked over the 12-month default, to Sep 2027.

Scoring Open: judged on the close on Sep 30, 2027.

Source Citizens reiterates Summit Therapeutics stock rating after AstraZeneca deal Investing.com · Sep 30, 2026 · opens the publisher's site
Citizens reiterates Summit Therapeutics stock rating after AstraZeneca deal

Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. “At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.

Summit Therapeutics revenue & net income history (FY2019–FY2025)

RevenueNet incomeNet margin (right axis, %)
$57.1M−$511.2M−$1.08BFY2019 revenue: $57.1MFY2019 net income: $10.9M · Net margin 19.0%'19FY2020 revenue: $860.0KFY2020 net income: −$52.7M · Net margin −6127.6%'20FY2021 revenue: $1.81MFY2021 net income: −$88.6M · Net margin −4897.8%'21FY2022 revenue: $705.0KFY2022 net income: −$78.8M · Net margin −11174.8%'22FY2023 revenue: $0FY2023 net income: −$614.9M'23FY2024 revenue: $0FY2024 net income: −$221.3M'24FY2025 net income: −$1.08B'25−360.0%−300%−200%−100%0%FY2019 net margin: 19.0%FY2020 net margin: −6127.6% (off the scale, which stops at −360.0%)FY2021 net margin: −4897.8% (off the scale, which stops at −360.0%)FY2022 net margin: −11174.8% (off the scale, which stops at −360.0%)
Summit Therapeutics annual financial statements
FY2019Jan 2019FY2020Dec 2020FY2021Dec 2021FY2022Dec 2022FY2023Dec 2023FY2024Dec 2024FY2025Dec 2025
Income statement
Revenue$57.1M$860.0K$1.81M$705.0K$0$0—
Growth (year over year)—−98.5%+110.3%−61.0%−100.0%——
Operating income$5.39M−$53.2M−$86.2M−$72.1M−$609.6M−$226.0M—
Operating margin9.4%−6185.2%−4764.3%−10225.4%———
Net income$10.9M−$52.7M−$88.6M−$78.8M−$614.9M−$221.3M−$1.08B
Net margin19.0%−6127.6%−4897.8%−11174.8%———
EPS (diluted)$0.63−$0.76−$0.67−$0.41−$0.99−$0.31−$1.44
Balance sheet
Cash and equivalents$35.2M$66.4M$71.8M$348.6M$71.4M$104.9M$225.3M
Total assets—$102.5M$113.4M$664.2M$202.9M$435.6M$751.2M
Total liabilities—$23.0M$30.1M$537.5M$125.3M$46.8M$92.3M
Shareholders' equity$57.6M$79.5M$83.3M$126.7M$77.7M$388.7M$658.9M
Cash flow
Operating cash flow−$35.1M−$48.1M−$72.6M−$41.6M−$76.8M−$142.1M−$322.9M
Capital expenditure$157.0K$421.0K$306.0K$624.0K$128.0K$139.0K$657.0K
Free cash flow−$35.3M−$48.5M−$72.9M−$42.2M−$76.9M−$142.2M−$323.6M
Dividends paid$0$0—————

From Summit Therapeutics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

Summit Therapeutics in the news

Nov 20, 2026 Yahoo Finance Wall Street Wrap: ASTS, BE, MDB Stocks Win Bullish Calls As PEP, USAR, SMMT Face Downgrades

Also mentions AST SpaceMobile, MongoDB, PepsiCo, USA Rare Earth Inc Class a

Nov 17, 2026 MarketWatch Summit Therapeutics’ stock tumbles again as FDA recommends new trial for lung-cancer drug
Nov 16, 2026 TradingView SMMT Stock Sees Price Target Reductions – A Look At What Analysts Said About FDA’s Complete Response Letter
Nov 16, 2026 MarketWatch The FDA declined to approve one of biotech’s most closely watched cancer drugs. The company’s stock tumbled.
Nov 15, 2026 TradingView Dow, S&P 500, Nasdaq Futures Edge Lower As Markets Brace For Nvidia Earnings, Anthropic IPO, Fed Minutes: SMMT, NBIS, HELP, MSTR In Focus
Show 4 older stories
Nov 15, 2026 Investing.com Jefferies reiterates Summit Therapeutics stock rating after FDA setback Target
Oct 5, 2026 Investing.com Bernstein reiterates Summit Therapeutics stock rating on trial concerns Target
Sep 30, 2026 Investing.com Citizens reiterates Summit Therapeutics stock rating after AstraZeneca deal Target
Tracked from this story

Also mentions AstraZeneca

Sep 29, 2026 Seeking Alpha Biggest stock movers Tuesday: FICO, CCL, SMMT, NVTS, and more

About Summit Therapeutics

Headquarters
Miami, Florida From SEC filings, Oct 2026

More Health Care stocks

Browse all companies →